IL124352A0 - Salts of quinoline derivatives as nk3 antagonists - Google Patents

Salts of quinoline derivatives as nk3 antagonists

Info

Publication number
IL124352A0
IL124352A0 IL12435296A IL12435296A IL124352A0 IL 124352 A0 IL124352 A0 IL 124352A0 IL 12435296 A IL12435296 A IL 12435296A IL 12435296 A IL12435296 A IL 12435296A IL 124352 A0 IL124352 A0 IL 124352A0
Authority
IL
Israel
Prior art keywords
antagonists
salts
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
IL12435296A
Other languages
English (en)
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of IL124352A0 publication Critical patent/IL124352A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12435296A 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists IL124352A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds
PCT/EP1996/005210 WO1997019928A1 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Publications (1)

Publication Number Publication Date
IL124352A0 true IL124352A0 (en) 1998-12-06

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12435296A IL124352A0 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Country Status (23)

Country Link
US (3) US6355654B1 (xx)
EP (1) EP0876348B1 (xx)
JP (1) JP4377454B2 (xx)
KR (1) KR19990071599A (xx)
CN (1) CN1207728A (xx)
AR (1) AR004970A1 (xx)
AT (1) ATE233243T1 (xx)
AU (1) AU722451B2 (xx)
BR (1) BR9611729A (xx)
CA (1) CA2238312A1 (xx)
CZ (1) CZ158198A3 (xx)
DE (1) DE69626416T2 (xx)
ES (1) ES2192621T3 (xx)
GB (1) GB9524137D0 (xx)
HU (1) HUP9903584A3 (xx)
IL (1) IL124352A0 (xx)
MX (1) MX9804106A (xx)
NO (1) NO310866B1 (xx)
NZ (1) NZ323389A (xx)
PL (1) PL326927A1 (xx)
TR (1) TR199800925T2 (xx)
WO (1) WO1997019928A1 (xx)
ZA (1) ZA969812B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
MX2007014831A (es) * 2005-06-03 2008-02-15 Astrazeneca Ab Derivados de quinolina como antagonistas de neurocinina-3.
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
WO2007016609A2 (en) * 2005-08-02 2007-02-08 Smithkline Beecham Corporation Method for the synthesis of quinoliνe derivatives
WO2007018469A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
EP1940795A1 (en) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
CA2853923A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316571B1 (ko) * 1994-05-27 2002-05-30 파올로 비지, 엔리꼬 카쭐라니 타키키닌nk3수용체길항제로서퀴놀린유도체
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
MX9804106A (es) 1998-09-30
NZ323389A (en) 2000-02-28
ES2192621T3 (es) 2003-10-16
JP2000500770A (ja) 2000-01-25
GB9524137D0 (en) 1996-01-24
DE69626416T2 (de) 2003-12-24
TR199800925T2 (xx) 2001-05-21
AU1031997A (en) 1997-06-19
HUP9903584A2 (hu) 2000-02-28
US20020156097A1 (en) 2002-10-24
US20020077335A1 (en) 2002-06-20
DE69626416D1 (de) 2003-04-03
CZ158198A3 (cs) 1998-10-14
ZA969812B (en) 1998-05-22
US6355654B1 (en) 2002-03-12
ATE233243T1 (de) 2003-03-15
AU722451B2 (en) 2000-08-03
AR004970A1 (es) 1999-04-07
EP0876348A1 (en) 1998-11-11
NO310866B1 (no) 2001-09-10
JP4377454B2 (ja) 2009-12-02
BR9611729A (pt) 1999-04-06
HUP9903584A3 (en) 2001-10-29
NO982332L (no) 1998-05-22
US6432977B1 (en) 2002-08-13
EP0876348B1 (en) 2003-02-26
WO1997019928A1 (en) 1997-06-05
CN1207728A (zh) 1999-02-10
KR19990071599A (ko) 1999-09-27
PL326927A1 (en) 1998-11-09
NO982332D0 (no) 1998-05-22
CA2238312A1 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
PL317381A1 (en) Derivatives of quinoline as antagonists of tachykynin receptors nk3
CY2505B1 (en) Quinoline derivatives as nk3 antagonists
PL326967A1 (en) Quinoline derivatives
HUP9802940A2 (hu) Kinolin-2(1H)-on-származékok mint szerotoninantagonisták
HUP9903584A3 (en) Salts of quinoline derivatives as nk3 antagonists
GR3036346T3 (en) BENZO[g]QUINOLINE DERIVATIVES
IL128141A0 (en) Tetrahydroquinoline derivatives as eaa antagonists
PL326636A1 (en) Derivatives of quinoline as inhibitors of type iv phosphodiesterase
EP1017676A4 (en) METHOD FOR PRODUCING CHINOLINE DERIVATIVES
PL333079A1 (en) Piparazinic derivatives as antagonists of neurokinin
GB9404378D0 (en) Quinoline derivatives
ZA954269B (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
GB9413150D0 (en) Quinoline derivatives
PL330723A1 (en) Derivatives of benzo[g]quinoline
HU9900343D0 (en) Use of quinoline derivatives having tachycinin nk3 receptor antagonist
PL318106A1 (en) Quinoline derivatives as antagonists of leucotrienes
SI0940391T1 (en) Quinoline derivatives as tachykinin NK3 receptor antagonists
GB9402306D0 (en) Quinoline derivatives
IL126806A0 (en) Quinoline derivatives